194 related articles for article (PubMed ID: 15733832)
1. Tumor therapeutics by design: targeting and activation of death receptors.
Wajant H; Gerspach J; Pfizenmaier K
Cytokine Growth Factor Rev; 2005 Feb; 16(1):55-76. PubMed ID: 15733832
[TBL] [Abstract][Full Text] [Related]
2. Targeting death receptors in cancer with Apo2L/TRAIL.
Kelley SK; Ashkenazi A
Curr Opin Pharmacol; 2004 Aug; 4(4):333-9. PubMed ID: 15251125
[TBL] [Abstract][Full Text] [Related]
3. Death ligands designed to kill: development and application of targeted cancer therapeutics based on proapoptotic TNF family ligands.
Gerspach J; Wajant H; Pfizenmaier K
Results Probl Cell Differ; 2009; 49():241-73. PubMed ID: 19142623
[TBL] [Abstract][Full Text] [Related]
4. Protein-based therapeutic approaches targeting death receptors.
French LE; Tschopp J
Cell Death Differ; 2003 Jan; 10(1):117-23. PubMed ID: 12655300
[TBL] [Abstract][Full Text] [Related]
5. Combining proteasome inhibition with TNF-related apoptosis-inducing ligand (Apo2L/TRAIL) for cancer therapy.
Sayers TJ; Murphy WJ
Cancer Immunol Immunother; 2006 Jan; 55(1):76-84. PubMed ID: 15864587
[TBL] [Abstract][Full Text] [Related]
6. Emerging applications of the tumor necrosis factor family of ligands and receptors in cancer therapy.
Younes A; Kadin ME
J Clin Oncol; 2003 Sep; 21(18):3526-34. PubMed ID: 12972530
[TBL] [Abstract][Full Text] [Related]
7. TRAIL and malignant glioma.
Hawkins CJ
Vitam Horm; 2004; 67():427-52. PubMed ID: 15110189
[TBL] [Abstract][Full Text] [Related]
8. Intracellular mechanisms of TRAIL and its role in cancer therapy.
Srivastava RK
Mol Cell Biol Res Commun; 2000 Aug; 4(2):67-75. PubMed ID: 11170835
[No Abstract] [Full Text] [Related]
9. Crosstalk between extrinsic and intrinsic cell death pathways in pancreatic cancer: synergistic action of estrogen metabolite and ligands of death receptor family.
Basu A; Castle VP; Bouziane M; Bhalla K; Haldar S
Cancer Res; 2006 Apr; 66(8):4309-18. PubMed ID: 16618756
[TBL] [Abstract][Full Text] [Related]
10. Targeted induction of apoptosis in cancer management: the emerging role of tumor necrosis factor-related apoptosis-inducing ligand receptor activating agents.
Rowinsky EK
J Clin Oncol; 2005 Dec; 23(36):9394-407. PubMed ID: 16361639
[TBL] [Abstract][Full Text] [Related]
11. Potential mechanism of resistance to TRAIL-induced apoptosis in Burkitt's lymphoma.
Tafuku S; Matsuda T; Kawakami H; Tomita M; Yagita H; Mori N
Eur J Haematol; 2006 Jan; 76(1):64-74. PubMed ID: 16343273
[TBL] [Abstract][Full Text] [Related]
12. Targeting death receptors in bladder, prostate and renal cancer.
O'Kane HF; Watson CJ; Johnston SR; Petak I; Watson RW; Williamson KE
J Urol; 2006 Feb; 175(2):432-8. PubMed ID: 16406966
[TBL] [Abstract][Full Text] [Related]
13. Specific resistance upon lentiviral TRAIL transfer by intracellular retention of TRAIL receptors.
Wenger T; Mattern J; Penzel R; Gassler N; Haas TL; Sprick MR; Walczak H; Krammer PH; Debatin KM; Herr I
Cell Death Differ; 2006 Oct; 13(10):1740-51. PubMed ID: 16470224
[TBL] [Abstract][Full Text] [Related]
14. Cancer gene therapy using a novel secretable trimeric TRAIL.
Kim CY; Jeong M; Mushiake H; Kim BM; Kim WB; Ko JP; Kim MH; Kim M; Kim TH; Robbins PD; Billiar TR; Seol DW
Gene Ther; 2006 Feb; 13(4):330-8. PubMed ID: 16195699
[TBL] [Abstract][Full Text] [Related]
15. Identification of small molecules that sensitize resistant tumor cells to tumor necrosis factor-family death receptors.
Schimmer AD; Thomas MP; Hurren R; Gronda M; Pellecchia M; Pond GR; Konopleva M; Gurfinkel D; Mawji IA; Brown E; Reed JC
Cancer Res; 2006 Feb; 66(4):2367-75. PubMed ID: 16489043
[TBL] [Abstract][Full Text] [Related]
16. The involvement of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in atherosclerosis.
Michowitz Y; Goldstein E; Roth A; Afek A; Abashidze A; Ben Gal Y; Keren G; George J
J Am Coll Cardiol; 2005 Apr; 45(7):1018-24. PubMed ID: 15808757
[TBL] [Abstract][Full Text] [Related]
17. Death to the bad guys: targeting cancer via Apo2L/TRAIL.
Bouralexis S; Findlay DM; Evdokiou A
Apoptosis; 2005 Jan; 10(1):35-51. PubMed ID: 15711921
[TBL] [Abstract][Full Text] [Related]
18. Modulation of death receptor pathways in oncology.
de Vries EG; Timmer T; Mulder NH; van Geelen CM; van der Graaf WT; Spierings DC; de Hooge MN; Gietema JA; de Jong S
Drugs Today (Barc); 2003; 39 Suppl C():95-109. PubMed ID: 14988748
[TBL] [Abstract][Full Text] [Related]
19. The promise of cancer therapeutics targeting the TNF-related apoptosis-inducing ligand and TRAIL receptor pathway.
Wang S
Oncogene; 2008 Oct; 27(48):6207-15. PubMed ID: 18931688
[TBL] [Abstract][Full Text] [Related]
20. Involvement of tumor necrosis factor-related apoptosis-inducing ligand and tumor necrosis factor-related apoptosis-inducing ligand receptors in viral hepatic diseases.
Saitou Y; Shiraki K; Fuke H; Inoue T; Miyashita K; Yamanaka Y; Yamaguchi Y; Yamamoto N; Ito K; Sugimoto K; Nakano T
Hum Pathol; 2005 Oct; 36(10):1066-73. PubMed ID: 16226105
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
